What is Macomics?
Founded in 2019 and based at the University of Edinburgh, Macomics is dedicated to developing novel therapies that precisely target macrophages, particularly tumor-associated macrophages (TAMs), for the treatment of cancer. The company leverages its deep expertise in macrophage biology and a proprietary target discovery platform to identify and validate new therapeutic targets. Macomics is progressing a diversified portfolio of antibody programs aimed at clinical advancement, with a strategic focus on enhancing the efficacy of cancer treatments by manipulating the tumor microenvironment.
How much funding has Macomics raised?
Macomics has raised a total of $5.9M across 1 funding round:
Unspecified
$5.9M
Unspecified (2021): $5.9M with participation from Scottish Enterprise, Epidarex Capital, and Caribou Property Limited
Key Investors in Macomics
Scottish Enterprise
Scottish Enterprise is a national economic development agency based in the United Kingdom, focused on fostering business growth and innovation across Scotland.
Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm specializing in early-stage life science companies, known for its deep scientific expertise and strategic partnerships with founders.
Caribou Property Limited
Caribou Property Limited is an entity participating in the funding round, with specific investment focus details not publicly disclosed.
What's next for Macomics?
The recent major strategic investment, alongside the planned Series A financing, is poised to accelerate Macomics' progress. The capital infusion will be instrumental in advancing its antibody programs towards clinical trials, expanding its pipeline of precision medicines, and further enhancing its cutting-edge target discovery technology. This strategic backing positions Macomics to solidify its standing in the competitive oncology landscape and bring its innovative macrophage-modulating therapies to patients.
See full Macomics company page
